157 related articles for article (PubMed ID: 33389242)
1. A novel method to detect intracellular metabolite alterations in MCF-7 cells by doxorubicin induced cell death.
Kumar A; Patel S; Bhatkar D; Sarode SC; Sharma NK
Metabolomics; 2021 Jan; 17(1):3. PubMed ID: 33389242
[TBL] [Abstract][Full Text] [Related]
2. Metabolomic Identification of Anticancer Metabolites of Australian Propolis and Proteomic Elucidation of Its Synergistic Mechanisms with Doxorubicin in the MCF7 Cells.
Alsherbiny MA; Bhuyan DJ; Radwan I; Chang D; Li CG
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360606
[TBL] [Abstract][Full Text] [Related]
3. Investigations on the cell metabolomics basis of multidrug resistance from tumor cells by ultra-performance liquid chromatography-mass spectrometry.
Zhang R; Zhuang X; Zong L; Liu S; Liu Z; Song F
Anal Bioanal Chem; 2016 Aug; 408(21):5843-5854. PubMed ID: 27379392
[TBL] [Abstract][Full Text] [Related]
4. A P-glycoprotein- and MRP1-independent doxorubicin-resistant variant of the MCF-7 breast cancer cell line with defects in caspase-6, -7, -8, -9 and -10 activation pathways.
Park SJ; Wu CH; Safa AR
Anticancer Res; 2004; 24(1):123-31. PubMed ID: 15015586
[TBL] [Abstract][Full Text] [Related]
5. Undetectable Free Aromatic Amino Acids in Nails of Breast Carcinoma: Biomarker Discovery by a Novel Metabolite Purification VTGE System.
Mitruka M; Gore CR; Kumar A; Sarode SC; Sharma NK
Front Oncol; 2020; 10():908. PubMed ID: 32695662
[No Abstract] [Full Text] [Related]
6. Fas/FasL-dependent and -independent activation of caspase-8 in doxorubicin-treated human breast cancer MCF-7 cells: ADAM10 down-regulation activates Fas/FasL signaling pathway.
Liu WH; Chang LS
Int J Biochem Cell Biol; 2011 Dec; 43(12):1708-19. PubMed ID: 21854868
[TBL] [Abstract][Full Text] [Related]
7. Synergic Effects of Doxorubicin and Melatonin on Apoptosis and Mitochondrial Oxidative Stress in MCF-7 Breast Cancer Cells: Involvement of TRPV1 Channels.
Koşar PA; Nazıroğlu M; Övey İS; Çiğ B
J Membr Biol; 2016 Apr; 249(1-2):129-40. PubMed ID: 26525975
[TBL] [Abstract][Full Text] [Related]
8. Mitochondria-Targeted Doxorubicin: A New Therapeutic Strategy against Doxorubicin-Resistant Osteosarcoma.
Buondonno I; Gazzano E; Jean SR; Audrito V; Kopecka J; Fanelli M; Salaroglio IC; Costamagna C; Roato I; Mungo E; Hattinger CM; Deaglio S; Kelley SO; Serra M; Riganti C
Mol Cancer Ther; 2016 Nov; 15(11):2640-2652. PubMed ID: 27466354
[TBL] [Abstract][Full Text] [Related]
9. Doxorubicin resistance mediated by cytoplasmic macrophage colony-stimulating factor is associated with switch from apoptosis to autophagic cell death in MCF-7 breast cancer cells.
Zhang M; Zhang H; Tang F; Wang Y; Mo Z; Lei X; Tang S
Exp Biol Med (Maywood); 2016 Dec; 241(18):2086-2093. PubMed ID: 27439542
[TBL] [Abstract][Full Text] [Related]
10. Schisandrin A reverses doxorubicin-resistant human breast cancer cell line by the inhibition of P65 and Stat3 phosphorylation.
Zhang ZL; Jiang QC; Wang SR
Breast Cancer; 2018 Mar; 25(2):233-242. PubMed ID: 29181822
[TBL] [Abstract][Full Text] [Related]
11. Folate-mediated mitochondrial targeting with doxorubicin-polyrotaxane nanoparticles overcomes multidrug resistance.
Wang H; Yin H; Yan F; Sun M; Du L; Peng W; Li Q; Feng Y; Zhou Y
Oncotarget; 2015 Feb; 6(5):2827-42. PubMed ID: 25605018
[TBL] [Abstract][Full Text] [Related]
12. An Intracellular Tripeptide Arg-His-Trp of Serum Origin Detected in MCF-7 Cells is a Possible Agonist to β2 Adrenoceptor.
Chandore H; Raj AK; Lokhande KB; Swamy KV; Pal JK; Sharma NK
Protein Pept Lett; 2021; 28(10):1191-1202. PubMed ID: 34397320
[TBL] [Abstract][Full Text] [Related]
13. Targeting P-glycoprotein function, p53 and energy metabolism: Combination of metformin and 2-deoxyglucose reverses the multidrug resistance of MCF-7/Dox cells to doxorubicin.
Xue C; Wang C; Sun Y; Meng Q; Liu Z; Huo X; Sun P; Sun H; Ma X; Ma X; Peng J; Liu K
Oncotarget; 2017 Jan; 8(5):8622-8632. PubMed ID: 28052008
[TBL] [Abstract][Full Text] [Related]
14. Azacytidine-induced Chemosensitivity to Doxorubicin in Human Breast Cancer MCF7 Cells.
Khan GN; Kim EJ; Shin TS; Lee SH
Anticancer Res; 2017 May; 37(5):2355-2364. PubMed ID: 28476801
[TBL] [Abstract][Full Text] [Related]
15. Reversal of doxorubicin resistance in breast cancer by mitochondria-targeted pH-responsive micelles.
Yu P; Yu H; Guo C; Cui Z; Chen X; Yin Q; Zhang P; Yang X; Cui H; Li Y
Acta Biomater; 2015 Mar; 14():115-24. PubMed ID: 25498306
[TBL] [Abstract][Full Text] [Related]
16. Doxorubicin-formaldehyde conjugate, doxoform: induction of apoptosis relative to doxorubicin.
Burke PJ; Koch TH
Anticancer Res; 2001; 21(4A):2753-60. PubMed ID: 11724351
[TBL] [Abstract][Full Text] [Related]
17. Discovery of IL-18 as a novel secreted protein contributing to doxorubicin resistance by comparative secretome analysis of MCF-7 and MCF-7/Dox.
Yao L; Zhang Y; Chen K; Hu X; Xu LX
PLoS One; 2011; 6(9):e24684. PubMed ID: 21931812
[TBL] [Abstract][Full Text] [Related]
18. Effect of β-elemene on the kinetics of intracellular transport of d-luciferin potassium salt (ABC substrate) in doxorubicin-resistant breast cancer cells and the associated molecular mechanism.
Tang CY; Zhu LX; Yu JD; Chen Z; Gu MC; Mu CF; Liu Q; Xiong Y
Eur J Pharm Sci; 2018 Jul; 120():20-29. PubMed ID: 29704644
[TBL] [Abstract][Full Text] [Related]
19. VCPA, a novel synthetic derivative of α-tocopheryl succinate, sensitizes human gastric cancer to doxorubicin-induced apoptosis via ROS-dependent mitochondrial dysfunction.
Wu H; Liu S; Gong J; Liu J; Zhang Q; Leng X; Zhang N; Li Y
Cancer Lett; 2017 May; 393():22-32. PubMed ID: 28216375
[TBL] [Abstract][Full Text] [Related]
20. N,N-Dimethyl phytosphingosine sensitizes HL-60/MX2, a multidrug-resistant variant of HL-60 cells, to doxorubicin-induced cytotoxicity through ROS-mediated release of cytochrome c and AIF.
Kim BM; Choi YJ; Lee YH; Joe YA; Hong SH
Apoptosis; 2010 Aug; 15(8):982-93. PubMed ID: 20512627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
